fluoxetine: the legal and safety record

The trial that was quietly over before the jury spoke

In September 1989, a month after starting fluoxetine, Joseph Wesbecker walked into the Louisville printing plant he had worked at and shot twenty people, killing eight, then himself. The survivors’ suit — Fentress v. Eli Lilly — went to trial in 1994 and returned a jury verdict for Lilly, cited for years afterward as Prozac’s exoneration. The trial judge, John Potter, suspected the contest had not been real: the plaintiffs had abruptly dropped their strongest evidence late in trial. The Kentucky Supreme Court let him investigate, finding “a serious lack of candor with the trial court” and that there “may have been deception, bad faith conduct, abuse of the judicial process or perhaps even fraud” [1]. Lilly was eventually forced to admit it had secretly settled with the plaintiffs during the trial — terms undisclosed to this day — and the judgment was changed from a defense verdict to “dismissed as settled” [2]. Judge Potter’s summary, as the BMJ reported it: “Lilly sought to buy not just the verdict but the court’s judgment as well” [2].

The verdict that was real

The editorial rule of this series cuts both ways, so say it plainly: in Forsyth v. Eli Lilly, a murder-suicide case tried to a federal jury in Honolulu, Lilly won a genuine defense verdict in spring 1999 (tried in March, verdict that April) [3]. No court has undone it. Whatever Fentress was, Forsyth was an adjudication on the merits, and any account of fluoxetine’s record that omits it is doing advocacy, not reporting.

What the regulator said — twice, thirteen years apart

In September 1991, at the height of the first Prozac-suicide controversy, an FDA advisory committee voted that the available evidence did not establish that antidepressants cause suicidality [4]. In October 2004, after re-analyzing pediatric trial data across the drug class, the FDA ordered the boxed warning that now opens every antidepressant label, fluoxetine’s included — verbatim from the current label: “Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies” [4][5]. Both votes are part of the record. A 1991 committee reading the evidence one way and a 2004 re-analysis reading new evidence the other way is how drug safety actually moves — slowly, and in public.

What is not in the record

• No DOJ marketing case for fluoxetine. Eli Lilly’s 2009 $1.4 billion federal resolution was about Zyprexa (olanzapine) — a different drug, covered on its own page — and importing it here would be exactly the blur this series exists to prevent.
• No Class I recall — seven enforcement records, all Class II [6].
• And in the drug’s favor: fluoxetine carries FDA pediatric approvals (depression and OCD) that most drugs in this series never obtained [5] — context that belongs next to the litigation, not buried under it.

Common questions

Did Eli Lilly win the Prozac mass-shooting lawsuit?

On paper, at first: the 1994 Fentress trial in Louisville — brought after Joseph Wesbecker killed eight coworkers and himself a month after starting fluoxetine — ended in a jury verdict for Lilly. But the trial judge suspected a deal, the Kentucky Supreme Court let him investigate (Potter v. Eli Lilly, 1996), and Lilly was eventually forced to admit it had secretly settled with the plaintiffs during the trial. The judgment was changed to 'dismissed as settled.' The judge's words, as reported by the BMJ: 'Lilly sought to buy not just the verdict but the court's judgment as well.'

Has any Prozac suicide-or-violence case actually been decided on the merits?

Yes — and the manufacturer won it. In Forsyth v. Eli Lilly, a murder-suicide case tried to a federal jury in Honolulu in March 1999 ended in a defense verdict that April. Unlike Fentress, no court has undone that outcome. A genuine defense verdict and a purchased-looking one sit side by side in this record, and this page reports both.

Does fluoxetine have a black box warning?

Yes — the class-wide suicidality warning the FDA ordered for all antidepressants in 2004 and extended to young adults in 2007. The current label's boxed warning begins: 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.' Notably, an FDA advisory committee had voted in September 1991 that the evidence then available did not establish that fluoxetine caused suicidality; the 2004 warning followed a re-analysis of pediatric trial data across the class.

Has fluoxetine been recalled?

No Class I recall appears in the openFDA enforcement database — seven records, all Class II. And in the other direction of the ledger: fluoxetine carries FDA pediatric approvals (depression and OCD) that most drugs in this series never obtained.

Thinking about fluoxetine itself, rather than its court history? The fluoxetine page has the approval basis, prescription volumes, and label warnings, sourced the same way.

Sources

Last verified 2026-09-01. Corrections change this date.